Aquatic Capital Management Boosts Vertex Pharmaceuticals Stake

Got story updates? Submit your updates here. ›

Aquatic Capital Management LLC, an investment management firm, purchased a new stake of 29,596 shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to a recent filing with the Securities and Exchange Commission. The shares were valued at approximately $11.6 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases, particularly cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many CF patients. Aquatic Capital's investment in Vertex signals confidence in the company's growth potential and pipeline.

The details

According to the SEC filing, Aquatic Capital Management purchased 29,596 shares of Vertex Pharmaceuticals in the third quarter. This new stake represents a significant investment for the firm, valued at around $11.6 million based on Vertex's share price at the time. Vertex Pharmaceuticals is a Boston-based biotech company that has become a leader in the development of therapies for cystic fibrosis and other serious diseases.

• Aquatic Capital Management purchased the 29,596 shares of Vertex Pharmaceuticals in the third quarter of 2026.